V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough
Biopharma & Life Sciences

Arvinas Executive Compensation (FY25)

ARVN · Executive and director compensation, fiscal 2022 to 2025
Latest say-on-pay support
=
June 24, 2026
Chief executive pay ratio
◇
To the median employee
Velarion Member: every covered company in Biopharma & Life Sciences, with dashboards, peer screens and board-ready briefs. Three seats, one year.
Email me this page as a cited PDF — sent in 2 minutes
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.

The paid brief on Arvinas

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
Data as of October 22, 2026Latest filing (8-K): June 25, 2026
10 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Arvinas brief$1,500Get the executive brief
Velarion Member, one year
332 figures on this page: 326 cited to the filing that reported them, 6 calculated from figures it prints. See the citations

More on Arvinas

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — John Houston: $12,746,981 → $6,534,127 (48.7% lower)
Say-on-pay support: 74.9% → 94.3% (19.4 points higher)
CEO pay ratio: 44:1 → 20:1 (54.5% lower)

Frequently asked questions

Answers drawn from the data on this page.
What was Arvinas' say-on-pay result?
Shareholders supported the say-on-pay proposal with 94.3% of votes cast for or against in favor at the meeting held June 24, 2026 for fiscal 2025.
Which companies are in Arvinas' peer group?
The disclosed peer group names Alector, Inc., Arcus Biosciences, Inc., Arrowhead Pharmaceuticals, Inc., Biohaven Ltd. and Cogent Biosciences, Inc., among others.
What is Arvinas' chief executive pay ratio?
For fiscal 2025, the company reported a chief executive pay ratio of 20:1, against median employee compensation of $327,724.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Houston
President and Chief Executive Officer
◇——◇◇—◇◇
Ronald Peck
Chief Medical Officer
◇——◇◇—◇◇
Ian Taylor
Chief Scientific Officer
◇——◇◇—◇◇
Sean Cassidy
Chief Financial Officer
◇——◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Houston
President and Chief Executive Officer
◇—◇◇◇—◇◇
Ian Taylor
Former President of Research and Development
◇—◇◇◇—◇◇
Sean Cassidy
Former Chief Financial Officer and Treasurer (6)
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Houston
President and Chief Executive Officer
◇—◇◇◇—◇◇
Noah Berkowitz
Chief Medical Officer
◇—◇◇◇—◇◇
Ian Taylor
Former President of Research and Development
◇—◇◇◇—◇◇
Randy Teel
Former interim Chief Financial Officer (5)
Departed during or after this year
◇—◇◇◇—◇◇
Andrew Saik
Chief Financial Officer
◇—◇◇◇—◇◇
Angela Cacace
Chief People Officer
◇—◇◇◇—◇◇
Sean Cassidy
Former Chief Financial Officer and Treasurer (6)
Departed during or after this year
◇—————◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
John Houston
Former President and Chief Executive Officer
Departed during or after this year
◇—◇◇◇—◇◇
Noah Berkowitz
Chief Medical Officer
◇—◇◇◇—◇◇
Andrew Saik
Chief Financial Officer and Treasurer
◇—◇◇◇—◇◇
Angela Cacace
Chief Scientific Officer
◇—◇◇◇—◇◇
Ian Taylor
Former President of Research and Development
Departed during or after this year
◇—◇◇——◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Andrew SaikOPTION◇——◇—◇◇
Andrew SaikOPTION◇——◇—◇◇
Andrew SaikRSU◇——◇——◇
Andrew SaikRSU◇——◇——◇
Andrew SaikOption——————◇
Angela CacaceOPTION◇——◇—◇◇
Angela CacaceOPTION◇——◇—◇◇
Angela CacaceOption——————◇
Angela Cacace, Ph.D.RSU◇——◇——◇
Angela Cacace, Ph.D.RSU◇——◇——◇
Ian TaylorOPTION◇——◇—◇◇
Ian Taylor, Ph.D.RSU◇——◇——◇
John HoustonRSU◇——◇——◇
John HoustonOPTION◇——◇—◇◇
Noah BerkowitzOption——————◇
Noah Berkowitz, M.D., Ph.DOPTION◇——◇—◇◇
Noah Berkowitz, M.D., Ph.DOPTION◇——◇—◇◇
Noah Berkowitz, M.D., Ph.D.RSU◇——◇——◇
Noah Berkowitz, M.D., Ph.D.RSU◇——◇——◇
Fiscal 2022, 2023, 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Angela CacaceRSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Option◇—◇—
John HoustonOption◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
Ian TaylorRSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
Andrew SaikRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
Noah BerkowitzRSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Severance and change in control

The terms as written in the agreements.
Andrew Saik
Chief Financial Officer and Treasurer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
Angela Cacace
Chief Scientific Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇
John Houston
Former President and Chief Executive Officer · Consulting agreement · citing a 2026 filing
Change-in-control trigger◇
Equity acceleration on change in control◇
Benefits continuation◇
Excise tax treatment◇
Non-compete period◇
Non-solicit period◇
Clawback◇
Noah Berkowitz
Chief Medical Officer · Terms as described in the company’s compensation discussion · citing a 2026 filing
Severance multiple◇
Severance base◇
Severance cash amount◇
Change-in-control multiple◇
Change-in-control base◇
Benefits continuation on change in control◇
Benefits continuation◇

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Briggs Morrison, M.D
Board chair
◇◇◇———◇
Linda Bain
◇◇◇———◇
Sunil Agarwal, M.D
◇◇◇———◇
Everett Cunningham
◇◇◇———◇
Leslie V. Norwalk, Esq
◇◇◇———◇
Laurie Smaldone Alsup, M.D
◇◇◇———◇
Edward Kennedy Jr
◇◇◇———◇
Randy Teel, Ph.D and John Houston, Ph.D served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Board chair premium◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alector, Inc. ALEC
  • Arcus Biosciences, Inc. RCUS
  • Arrowhead Pharmaceuticals, Inc. ARWR
  • Biohaven Ltd. BHVN
  • Cogent Biosciences, Inc. COGT
  • Crinetics Pharmaceuticals, Inc. CRNX
  • Denali Pharmaceuticals, Inc. DNLI
  • Erasca, Inc. ERAS
  • Intellia Therapeutics, Inc. NTLA
  • KalVista Pharmaceuticals, Inc. KALV
  • Prothena Corporation plc PRTA
  • REGENXBIO, Inc. RGNX
  • Relay Therapeutics, Inc. RLAY
  • SpringWorks Therapeutics, Inc. SWTX
  • Syndax Pharmaceuticals, Inc. SNDX
  • Xencor, Inc. XNCR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 24, 2026=◇◇◇
2024June 25, 2025=◇◇◇
2023May 29, 2024=◇◇◇
2022June 15, 2023=◇◇◇
2021June 16, 2022=◇◇◇
2020June 8, 2021=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇

Velarion Pro: every company page, peer tools and exports, one seat

One seat, one person. It opens the whole platform: the peer tools, the written analysis and the exports, on every company we cover. Join the list and you will hear from us when it opens.
Your address is used for this and nothing else, and you can unsubscribe in one click. See the privacy policy.

Ask our research desk — $99, 24h, every figure cited to its filing.

Sample answer — “What is the CEO’s total compensation?”
- John Houston (Former President and Chief Executive Officer), FY2025 total compensation $6,534,127 (base salary $706,236) [exec_comp, SEC accession 0001628280-26-028156, filed 2026-04-29]

Answered within 24 hours, every figure cited to its SEC filing. If our database cannot answer your question, you are refunded automatically.

Tell me when Arvinas files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Arvinas disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Arvinas sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $499
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for Peer Group Review
Whether Arvinas' disclosed peer group is defensible, who names Arvinas back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
332 figures on this page: 326 cited to the filing that reported them, 6 calculated from figures it prints.
326 cited to the filing
6 calculated from the filing

Documents cited

  1. 0001628280-26-045520
  2. 0001628280-26-028156
    2025 Summary Compensation Table · Compensation Discussion and Analysis · Director Compensation · EXECUTIVE AND DIRECTOR COMPENSATION · and 4 more sections
  3. 0001655759-25-000128
  4. 0001655759-25-000075
  5. 0001655759-24-000070
  6. 0001655759-23-000073
  7. 0001655759-23-000034
  8. 0001655759-22-000020
    Item 5.07 Submission of Matters to a Vote of Security Holders
  9. 0001193125-21-186693
    Item 5.07 Submission of Matters to a Vote of Security Holders
  10. 0001628280-26-011226
    Exhibit
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Arvinas executive compensation, FY2022–FY2025.” https://intel.velarion.ai/comp/ARVN (accessed 2026).
Short form: data: Velarion

The paid brief for Arvinas

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $499 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
10 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Arvinas and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Biopharma & Life Sciences rankings

Chief executive pay — Biopharma & Life SciencesCEO pay ratio — Biopharma & Life SciencesSay-on-pay support — Biopharma & Life Sciences

Peers Arvinas discloses

The companies named in ARVN's own disclosed peer group.

Alector, Inc.Arcus Biosciences, Inc.Arrowhead Pharmaceuticals, Inc.Biohaven Ltd.Cogent Biosciences, Inc.Crinetics Pharmaceuticals, Inc.Denali Pharmaceuticals, Inc.Erasca, Inc.Intellia Therapeutics, Inc.KalVista Pharmaceuticals, Inc.Prothena Corporation plcREGENXBIO, Inc.Relay Therapeutics, Inc.SpringWorks Therapeutics, Inc.Syndax Pharmaceuticals, Inc.Xencor, Inc.

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy